Seekingalpha.com
0
All posts from Seekingalpha.com
Seekingalpha.com in Seekingalpha.com,

Intrexon's (XON) CEO Randal Kirk on Q2 2015 Results - Earnings Call Transcript

Operator

Good afternoon and welcome to the Intrexon Corporation First Half and Second Quarter 2015 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I’d now like to turn the conference over to Christopher Basta. Please go ahead.

Christopher Basta - IR

Good afternoon. I am Chris Basta, Vice President of Investor Relations for Intrexon Corporation. Welcome to our second quarter 2015 earnings conference call. Joining me on the call today are Mr. Randal Kirk, Chairman and Chief Executive Officer, and Mr. Krish Krishnan, Chief Operating Officer.

During this conference call, we will make various forward-looking statements within the meaning of the Safe Harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of the business, of Intrexon are based on current expectations, are subject to risks and uncertainties.

A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. Please read the Safe Harbor statement contained in the earnings press release, which was released earlier today, and is also available on our Web site under the Investors link, as well as Intrexon's most recent SEC filings, for a more complete description.

The press release references and our discussion this afternoon I reference certain non-GAAP financial measures, including adjusted EBITDA, earnings per share, pro-forma adjusted EBITDA earnings per share and pro-forma net income. Reconciliations to GAAP measures are contained in the earnings press release, as well as on the Investor section on our Web site at www.dna.com.

Now I’d like to turn the call over to Krish Krishnan, our Chief Operating Officer. Krish, the floor is yours.

Krish S. Krishnan - COO

Thanks, Chris. Good afternoon, everyone and thanks for joining the call today. R.J and I are pleased with Intrexon's performance in the second quarter of 2015. We’ve recognized that biology can both inspire and create revolutionary solutions to the world’s pressing problems, decoupled passion with a socially conscious purpose empowering people to realize the products of a better, cleaner, healthier planet.

And during the second quarter, we continue to progress our leadership position in the engineering of biology. Within the health sector, our momentum continues to build as we pursue the potential of gene and cell therapies to make a difference in patient’s lives.

During the quarter, some of our collaborators entered the clinic, announced that intend to enter the clinic, enabled by Intrexon’s platform to fight a number of diseases. ZIOPHARM has begun to recruit patients in clinical trials against brain cancer and breast cancer, using the RheoSwitch controlled IL-12.

The ability to tune and regulate the expression of this powerful cytokine and a broad array of other genes via our RheoSwitch technology opens the door to safer approaches within the growing field of gene therapy.

Fibrocell Science filed an IND for its lead gene therapy candidate, utilizing an autologous cell platform engineered to express collagen 7, for the treatment of debilitating genetic skin disorder known as RDEB.

Oragenics is pursuing the development of biotherapeutics for oral mucositis, including clinical advancement of ActoBiotics, AG013. Oral mucositis is among the most frequently reported adverse events associated with cancer therapy affecting up to 500,000 patients annually and AG013 offers a convenient oral treatment to deliver therapeutics that protect against and repair chemo radiation induced damage of mucosal tissue.


More